Dawn Carter Bir's Insider Trades & SAST Disclosures
Dawn Carter Bir's most recent trade in Soleno Therapeutics Inc was a trade of 13,000 Common Stock done . Disclosure was reported to the exchange on Aug. 15, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Dawn Carter Bir.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | Dawn Carter Bir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 13,000 | 13,000 (0%) | 0% | 0 | Common Stock | |
| Geron Corp. | Dawn Carter Bir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 169.04 per share. | 15 Aug 2023 | 807 | 34,203 (0%) | 0% | 169.0 | 136,413 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 168.33 per share. | 15 Aug 2023 | 398 | 33,805 (0%) | 0% | 168.3 | 66,996 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 40,000 | 40,000 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 28 Jul 2023 | 40,000 | 75,010 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 164.54 per share. | 28 Jul 2023 | 40,000 | 35,010 (0%) | 0% | 164.5 | 6,581,428 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 40,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 28 Jul 2023 | 40,000 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2023 | 4,125 | 35,010 (0%) | 0% | 0 | Class A common stock | |
| Geron Corp. | Dawn Carter Bir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.09 per share. | 15 May 2023 | 894 | 31,302 (0%) | 0% | 85.1 | 76,070 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 80.95 per share. | 15 May 2023 | 417 | 30,885 (0%) | 0% | 81.0 | 33,758 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 86.77 per share. | 13 Mar 2023 | 9,317 | 32,196 (0%) | 0% | 86.8 | 808,436 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2023 | 48,370 | 48,370 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2023 | 48,370 | 41,630 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 06 Mar 2023 | 48,370 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 06 Mar 2023 | 48,370 | 96,879 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 06 Mar 2023 | 41,630 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2023 | 41,630 | 41,630 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2023 | 41,630 | 0 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 06 Mar 2023 | 41,630 | 83,555 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 89.30 per share. | 06 Mar 2023 | 40,134 | 56,745 (0%) | 0% | 89.3 | 3,583,966 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.08 per share. | 06 Mar 2023 | 36,049 | 47,506 (0%) | 0% | 85.1 | 3,067,049 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 90.26 per share. | 06 Mar 2023 | 14,820 | 41,925 (0%) | 0% | 90.3 | 1,337,653 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.90 per share. | 06 Mar 2023 | 5,793 | 41,713 (0%) | 0% | 85.9 | 497,619 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 86.67 per share. | 06 Mar 2023 | 200 | 41,513 (0%) | 0% | 86.7 | 17,334 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 88.25 per share. | 03 Mar 2023 | 2,166 | 48,509 (0%) | 0% | 88.2 | 191,148 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 63,650 | 63,650 | - | - | Employee Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 15,675 | 50,675 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 70,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 35,000 | 35,000 (0%) | 0% | 0 | Class A common stock | |
| Geron Corp. | Dawn Carter Bir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 16,500 | 16,500 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 09 Nov 2020 | 60,000 | 60,000 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 60,000 | 60,000 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 60,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | 09 Nov 2020 | 60,000 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 175.00 per share. | 09 Nov 2020 | 30,000 | 0 (0%) | 0% | 175 | 5,250,000 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Dawn Carter Bir | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 150.01 per share. | 09 Nov 2020 | 30,000 | 30,000 (0%) | 0% | 150.0 | 4,500,300 | Class A common stock |
| Geron Corp. | Dawn Carter Bir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 83,000 | 83,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges